
    
      A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb
      Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder
      (MDD) and a History of Inadequate Response to Antidepressants
    
  